[1st March 2017] A new report has been published by the All.Can group looking at the need to improve efficiency in cancer care by focusing on patient outcomes. IBTA Chair Kathy Oliver is a member of the All.Can initiative, as are leading cancer experts from the patient advocacy, medical, academic and industry spheres.
The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. Some of the highlights from the February issue include: Brain Tumour Awareness Month in the UK, the creation of a surgical probe the size of a human hair, the finding that drugs derived from chemicals in the cannabis plant may have a role in brain tumour palliative care…
The IBTA was delighted to exhibit at the 21st Society for Neuro-Oncology Annual Scientific Meeting, held at the Fairmont Princess Hotel in Scottsdale, Arizona, on 18-22 November 2016.
This year’s meeting was the largest ever, with over 2,350 attendees (200 more than 2015) and 1,024 abstracts submitted (100 more than last year). The IBTA was represented at the conference by Chair Kathy Oliver (UK) and Senior Advisor Chris Tse (New Zealand)…
On 11-14 September 2016, the 13th ASNO Annual Meeting and the 9th COGNO Annual Scientific Meeting were held in Sydney, Australia. The IBTA were exhibiting at this important event and we report back on the scientific meeting here.
The IBTA’s monthly e-News has now been released and has been emailed to all subscribers. Some of the highlights from the August issue include: The 10th International Brain Tumour Awareness Week is fast approaching and will be held from Saturday, 22nd October to Saturday, 29th October inclusive. No matter where you live…
Some of the highlights from the July issue include:
- A research study has found that gross total resection (complete tumour removal) extends survival in glioblastoma patients, compared to subtotal (incomplete) resection. A separate study on mice has found that glioma tumour cells left in the brain after removal surgery grow more aggressively than the original tumour.
- Research published in the British Journal of Cancer has made the unexpected finding that high blood sugar levels are linked to a reduced risk of meningioma.
- Experiments on mice have shown that glioma cells use fats (fatty acids) as their primary fuel source. It had been previously thought that glucose was the main fuel source for tumour cells. The authors suggest that previous research did not reflect how tumour cells actually function within the brain.
- Novocure's second generation Optune, a Tumor Treating Fields (TTFields) device, has been approved for use in the United States by the US Food and Drug Administration (FDA).
- A new version of the UK Cancer Drugs Fund (CDF) comes into effect on 29thJuly 2016. a coalition of 15 leading UK cancer charities previously expressed “deep concern” that the new CDF will ultimately reduce the number of patients receiving vital treatments.
- The FDA has granted Rare Pediatric Disease Designation for AbbVie’s ABT-414 - an antibody combined with a drug that targets epidermal growth factor receptor (EGFR) - for the treatment of paediatric patients with EGFR-amplified diffuse intrinsic pontine glioma (DIPG).
- You can read the IBTA e-News July edition online here
Our monthly e-News highlights items of interest to our international brain tumour community and is emailed to nearly 7,000 recipients. It gives a round-up of the latest research and treatment developments, news about brain tumour patient organisations around the world, and key forthcoming neuro-oncology scientific and patient conferences. You can sign up to receive the e-News by registering here.
To see an archive of existing e-News issues, click here.